Importance of [¹⁸F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma

References

• Morton L M, Wang S S, Devesa S S, Hartge P, Weisenburger D D, Linet M S. Lymphoma incidence patterns by WHO subtype in the United States, 1992 – 2001. Blood 2006; 107: 265–276
   PubMed Web of Science ®Google Scholar
• Homing S J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884
   PubMed Web of Science ®Google Scholar
• Young R C, Longo D L, Glastein E, Ihde D C, Jaffe E S, De Vita V T. The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin Hematol 1988; 25: 11–18
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Hurvitz S A, Timmerman J M. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol 2005; 17: 432–440
   PubMed Web of Science ®Google Scholar
• Hsu F J, Benike C, Fagnoni F, Liles T M, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–58
   PubMed Web of Science ®Google Scholar
• Timmerman J M, Czerwinski D K, Davis T A, Hsu F J, Benike C, Hao Z M, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004; 2: 27–37
   PubMedGoogle Scholar
• Zitvogel L, Tursz T. In vivo veritas. Nat Biotechnol 2005; 23: 1372–1374
   PubMed Web of Science ®Google Scholar
• Adams J Y, Johnson M, Sato M, Berger F, Gambhir S S, Carey M, et al. Visualization of advance human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002; 8: 891–897
   PubMed Web of Science ®Google Scholar
• Edinger M, Cao Y A, Verneris M R, Bachmann M H, Contag C H, Negrin R S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003; 101: 640–648
   PubMed Web of Science ®Google Scholar
• Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. PNAS 2003; 100: 1232–1237
   PubMed Web of Science ®Google Scholar
• Shozushima M, Tsutsumi R, Terasaki K, Sato S, Nakamura R, Sakamaki K. Augmentation effects of lymphocyte activation by antigen-presenting macrophage on FDG uptake. Ann Nucl Med 2003; 17: 555–560
   PubMed Web of Science ®Google Scholar
• Wallace M, Pyzalski R, Horejsh D, Brown C, Djavani M, Lu Y, et al. Whole body positron emission tomography imaging of activated lymphoid tissues during acute simian-human immunodeficiency virus 89.6PD infection in rhesus macaques. Virology 2000; 274: 255–261
   PubMed Web of Science ®Google Scholar
• Iyengar S, Chin B, Margolick J B, Sabundayo B P, Schwartz D H. Anatomical loci of HIV-associated immune activation and association with viremia. Lancet 2003; 362: 945–950
   PubMed Web of Science ®Google Scholar
• Harris N L. Principles of the revised European-American lymphoma classification (from the International Lymphoma Study Group). Ann Oncol 1997; 8: 11–16
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Tarte K, Fiol G, Rossi J F, Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 2000; 14: 2182–2192
   PubMed Web of Science ®Google Scholar
• Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643–4651
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793–800
   PubMed Web of Science ®Google Scholar
• Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging 1998; 1: 101–110
   PubMedGoogle Scholar
• Hicks R J, Mac Manus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165–175
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Hustinx R, Bequin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 185–196
   Web of Science ®Google Scholar
• Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Timothy A R, O'Doherty M J, Hain S, Maisey M N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543–553
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107: 175–183
   PubMed Web of Science ®Google Scholar
• Shu C, Guo S, Kim Y, Shelly S M, Nijagal A, Ray P, et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Nat Acad Sci USA 2005; 102: 17412–17417
   PubMed Web of Science ®Google Scholar